EMEA

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 16-17 January 2024

Retrieved on: 
Friday, January 19, 2024

CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Key Points: 


CVMP opinions on veterinary medicinal productsThe Committee adopted by consensus a positive opinion for a grouping of variations requiring assessment for Metacam (meloxicam), from…

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Retrieved on: 
Monday, January 8, 2024

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Yorvipath, Palopegteriparatide, Date of authorisation: 17/11/2023, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020.

Key Points: 
  • Hypoparathyroidism is rare, and Yorvipath was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 19 October 2020.
  • Teriparatide replaces the missing hormone in patients with hypoparathyroidism, acting through bone tissue and the kidneys to help restore calcium levels.
  • The European Medicines Agency therefore decided that Yorvipath’s benefits are greater than its risks and it can be authorised for use in the EU.
  • Yorvipath : EPAR - Medicine overview
    Product information
    Yorvipath : EPAR - Product information
    Latest procedure affecting product information: EMEA/H/C/005934
    This medicine’s product information is available in all official EU languages.

Human medicines European public assessment report (EPAR): Dimethyl fumarate Neuraxpharm, dimethyl fumarate, Date of authorisation: 13/05/2022, Revision: 5, Status: Withdrawn

Retrieved on: 
Tuesday, January 2, 2024

Overview

Key Points: 
  • Overview
    This marketing authorisation has been revoked by the European Commission in order to implement the judgment of the Court of Justice of 16 March 2023 in Commission and Others v Pharmaceutical Works Polpharma, Cases C-438/21 P to C-440/21 P.
    Dimethyl fumarate Neuraxpharm : EPAR - Medicine Overview
    Product information
    Dimethyl fumarate Neuraxpharm : EPAR - Product Information
    Latest procedure affecting product information: EMEA/H/C/006039
    13/12/2023
    This medicine’s product information is available in all official EU languages.
  • Select 'available languages' to access the language you need.
  • Product information documents contain:
    - summary of product characteristics (annex I);
    - manufacturing authorisation holder responsible for batch release (annex IIA);
    - conditions of the marketing authorisation (annex IIB);
    - labelling (annex IIIA);
    - package leaflet (annex IIIB).
  • Dimethyl fumarate Neuraxpharm : EPAR - All authorised presentations
    Product details
    - Name of medicine
    - Dimethyl fumarate Neuraxpharm
    - Active substance
    - dimethyl fumarate
    - International proprietary name (INN) or common name
    - dimethyl fumarate
    - Therapeutic area (MeSH)
    - Multiple Sclerosis, Relapsing-Remitting
    - Anatomical therapeutic chemical (ATC) code
    - L04AX07
    Pharmacotherapeutic groupImmunosuppressants
    Therapeutic indication
    Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

ManpowerGroup Talent Solutions' Total Workforce Index™ Reveals United States, Singapore, and Canada as the Top Markets for Talent

Retrieved on: 
Thursday, November 17, 2022

Now in its ninth year, the Total Workforce Index analyzes more than 200 factors to evaluate workforce availability, cost efficiency, regulation, and productivity across 69 markets.

Key Points: 
  • Now in its ninth year, the Total Workforce Index analyzes more than 200 factors to evaluate workforce availability, cost efficiency, regulation, and productivity across 69 markets.
  • MILWAUKEE, Nov. 17, 2022 /PRNewswire/ --The ManpowerGroup (NYSE: MAN) Talent Solutions 2022 Total Workforce Index (TWI) reveals the U.S., Singapore, and Canada as the highest-rankinglabor markets across the globe for sourcing, hiring, and retaining talent.
  • These findings were combined with big data and expert analysis to assess the workforce engagement of 69 global markets.
  • The markets that rank highest in the Total Workforce Index are those with the highest relative performance across all four categories.

Workout to Win: Amazfit Launches Challenge on adidas Apps Following Partnership Announcement

Retrieved on: 
Wednesday, November 16, 2022

CUPERTINO, Calif., Nov. 16, 2022 /PRNewswire/ -- Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has launched the Workout to Win challenge - the brand's first joint campaign with adidas Runtastic following the recent announcement of their collaboration.

Key Points: 
  • CUPERTINO, Calif., Nov. 16, 2022 /PRNewswire/ -- Amazfit , a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has launched the Workout to Win challenge - the brand's first joint campaign with adidas Runtastic following the recent announcement of their collaboration.
  • All entrants who sign up for the challenge on the adidas Running or adidas Training apps from November 17, 2022, will receive a 10% off coupon for Amazfit stores in their locality*.
  • They are the ideal companions for any fitness challenge, from outdoor GPS-assisted activities to gym workouts.
  • Moreover, most Amazfit wearables connected to the Zepp App now support syncing with adidas Running.

Workout to Win: Amazfit Launches Challenge on adidas Apps Following Partnership Announcement

Retrieved on: 
Wednesday, November 16, 2022

CUPERTINO, Calif., Nov. 16, 2022 /PRNewswire/ -- Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has launched the Workout to Win challenge - the brand's first joint campaign with adidas Runtastic following the recent announcement of their collaboration.

Key Points: 
  • All entrants who sign up for the challenge on the adidas Running or adidas Training apps from November 17, 2022, will receive a 10% off coupon for Amazfit stores in their locality*.
  • They are the ideal companions for any fitness challenge, from outdoor GPS-assisted activities to gym workouts.
  • Moreover, most Amazfit wearables connected to the Zepp App now support syncing with adidas Running.
  • With outstanding craftsmanship, Amazfit smartwatches have won many design awards, including the iF Design Award and the Red Dot Design Award.

BioLogiQ® is Pleased to Announce a Distribution Partnership with Plastrans, a Leading Provider of Foundational Plastic Resins Across Europe

Retrieved on: 
Wednesday, November 16, 2022

IDAHO FALLS, Idaho, Nov. 16, 2022 /PRNewswire/ -- BioLogiQ, developer of the innovative plant-powered iQ Technology and NuPlastiQBiopolymers, announced today a distribution agreement with Plastrans, Europe's leading provider of plastic resins.

Key Points: 
  • IDAHO FALLS, Idaho, Nov. 16, 2022 /PRNewswire/ -- BioLogiQ, developer of the innovative plant-powered iQ Technology and NuPlastiQBiopolymers, announced today a distribution agreement with Plastrans, Europe's leading provider of plastic resins.
  • iQ Technology "iQ" leverages NuPlastiQ, BioLogiQ's innovative 100% natural material that is derived from plants.
  • Once processed, it is incorporated into legacy or bioplastic based BioBlends to enable performance and environmental benefits not available with any other solution.
  • Plastrans' distribution of iQ Technology based NuPlastiQ resins means it also takes the lead in providing a natural solution for reducing the accumulation of plastic pollution on our land and in our oceans.

Liftoff's most comprehensive survey of global app marketers finds rising optimism amid macroeconomic and privacy challenges

Retrieved on: 
Wednesday, November 16, 2022

REDWOOD CITY, Calif., Nov. 16, 2022 /PRNewswire/ -- Liftoff, the leading growth acceleration platform for the mobile industry, today released the industry's most comprehensive survey of global app marketing professionals. Liftoff's 2022 App Marketer Survey brings together responses from over 500 mobile marketers, offering a detailed look at what it's like to run mobile marketing campaigns for an app right now – and what marketers see as the key trends ahead in 2023.

Key Points: 
  • Respondents were also asked their view on the current state of app marketing, and whether they are optimistic for the future of the space.
  • That's understandable, as app marketing has had a turbulent year with COVID-19 winding down, a tough macroeconomic climate and industry headwinds all combining to make life more difficult for marketers.
  • The survey also showed marketers turning to less trackable channels as a way of augmenting their mobile advertising campaigns.
  • The 2022 App Marketer Survey is based on a survey of 500+ app marketing professionals based in APAC, EMEA, North America, and LATAM.

FullStory Named to Deloitte Fast 500™ for Fourth Consecutive Year

Retrieved on: 
Wednesday, November 16, 2022

This marks the fourth year in a row that FullStory has made the prestigious list.

Key Points: 
  • This marks the fourth year in a row that FullStory has made the prestigious list.
  • The Deloitte Technology Fast 500 honors the companies that have prospered by anticipating what's next and understanding what's needed to succeed.
  • FullStory has grown more than 400% from 2018 to 2021, including posting record international growth across EMEA and APAC.
  • FullStory most recently launched the FullStory Community to helpDXI enthusiasts around the globe to create the next generation of digital experiences together.